CTLA4 and cancer: Thus, as evidence accumulates for the negative effects of T cell exhaustion on the outcome of cancer immunotherapy much ongoing effort is directed toward identifying targetable pathways and surface receptors other than CTLA-4 and PD-1, currently the only two targets for which there are licensed immunomodulatory antibodies available.